Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

Sponsor

M.D. Anderson Cancer Center (Other)

Overall Status

Withdrawn

CT.gov ID

NCT01432119

Collaborator

(none)

Enrollment

Arms

Study Details

Study Description

Brief Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of selective internal radiation (SIR)-Spheres with yttrium-90 attached and cetuximab. Some participants will also take erlotinib with this combination.

Yttrium-90 microspheres are designed to treat cancer that has spread to the liver. SIR-Spheres are designed to deliver the radiation directly to the liver. This radiation may cause the tumor cells to die.

Cetuximab and erlotinib are drugs that are designed to block the epidermal growth factor receptor (EGFR). EGFR is a protein that helps cancer cells grow. Blocking the EGFR may stop tumors from growing.

Condition or Disease	Intervention/Treatment	Phase
Advanced Cancers	Device: SIR-Spheres Drug: Cetuximab Drug: Erlotinib Procedure: Break-Through Scan	Phase 1

Detailed Description

Study Groups:

If you are found to be eligible to take part in this study, your doctor will decide which group you will be in based on your medical history.

Group 1 will receive SIR-Spheres with yttrium-90 attached and cetuximab.
Group 2 will receive SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib.

Once it is decided which combination you will receive, you will be assigned to a dose level of cetuximab based on when you join the study. Up to 3 dose levels of cetuximab will be tested. Three (3) to 6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable doses of the combinations are found.

All study participants will receive a dose level of the SIR-Spheres with yttrium-90 attached based on the results of the "break-through" scan (described below).

If you are assigned to Group 2, you will also receive erlotinib. If you are tolerating erlotinib well after 1 cycle, you may begin receiving a higher dose of erlotinib in Cycle 3 and beyond.

Break-through Scan:

You will have a "break-through" scan within 29 days before receiving the SIR-Spheres with yttrium-90 microspheres. This scan will measure the supply of blood in your lungs and will also be used to check your liver. For this test, a small amount of radioactive material will be injected into your liver and images will be taken to see how the material moves through your lungs and liver. The radioactive material will be given through a catheter in a vein in your groin. A catheter is a sterile, flexible tube that will be placed through your groin artery into the artery leading to your liver while you are under local anesthesia. Your doctor will explain this procedure to you in more detail.

The results of this test will be used to determine if you will receive a full or partial dose of SIR-Spheres with yttrium-90 microspheres.

Radiation and Study Drug Administration:

Each study cycle is 28 days.

You will receive the SIR-Spheres with yttrium-90 microspheres on Day 1 of Cycle 1 only. Before you receive the SIR-Spheres with Yttrium-90 microspheres, you will receive sedative drugs by vein to put you to sleep. SIR-Spheres with yttrium-90 microspheres will then be given to you through a catheter in a vein in your groin.

After you are given the yttrium-90 microspheres, the catheter will be removed and pressure will be applied to your groin to stop any bleeding. You will then be monitored for 6 hours to check for any side effects. If needed, you will be given pain medication after the infusion. Your study doctor will decide which pain medications to give you.

Cetuximab will be given by vein 1 time each week during Weeks 2-4 of Cycle 1, and then 1 time every week for Cycles 2 and beyond. The first time you receive cetuximab, it will be given over 2 hours. Every time you receive cetuximab after that, it will be given over 1 hour.

If you are assigned to receive erlotinib, you will take it by mouth 1 time each day starting on Day 1 of Cycle 2. You should take it at the same time each day . You should take it on an empty stomach either 1 hour before or 2 hours after eating. The study staff will give you more instructions for taking erlotinib.

Study Visits:

On Day 1 of Cycle 1:

Before you receive the SIR-Spheres with yttrium-90 microspheres, your blood vessels will be checked. For this test, you will receive an x-ray dye through the catheter that will help the study staff look at the arteries leading to your liver and surrounding areas.
You will have a physical exam and your medical history will be recorded.
Blood (about 2 teaspoons) will be drawn for routine tests.

During Weeks 2 and 4 of Cycle 1:

You will have a physical exam and your medical history will be recorded.
Blood (about 2 teaspoons) will be drawn for routine tests.

Every 8 weeks, you will have an x-ray, CT scan, MRI scan, and/or PET/CT scan to check the status of the disease.

About every 4 weeks starting at the beginning of Cycle 2:

You will have a physical exam and your medical history will be recorded
Blood (about 2 teaspoons) will be drawn for routine tests. This routine blood draw will include a pregnancy test if you are able to become pregnant.

Length of Study:

You receive the study drugs for as long as you are benefitting. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.

This is an investigational study. SIR-Spheres are FDA-approved and commercially available to treat metastatic colorectal cancer that has spread to the liver. Yttrium-90 microspheres are FDA-approved for hepatic arterial therapy and the treatment of liver metastases. Cetuximab is FDA-approved and commercially available to treat head and neck and colorectal cancer. Erlotinib is FDA-approved and commercially available to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. The use of this combination to treat advanced cancer is investigational.

Up to 136 patients will take part in this study. All will be enrolled at MD Anderson.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I Trial of Cetuximab and Erlotinib (EGFR Inhibitors) and SIR-Spheres (Yttrium Microspheres) in Patients With Advanced Malignancies and Liver Metastases

Study Start Date :

Dec 1, 2012

Anticipated Primary Completion Date :

Dec 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm 1 SIR-Spheres + Cetuximab Arm 1: SIR-Spheres with yttrium-90 attached and cetuximab. SIR-Spheres Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Nuclear medicine "break-through" scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered.	Device: SIR-Spheres 100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin. Drug: Cetuximab Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly. Other Names: C225 Erbitux Procedure: Break-Through Scan Nuclear medicine "break-through" scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered. Other Names: x-ray
Experimental: Arm 2 SIR-Spheres + Cetuximab + Erlotinib. Arm 2: SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib. Physicians will assign patients to Arm 1 or Arm 2 based on their discretion. SIR-Spheres on Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Erlotinib start 100 mg by mouth daily starting with Cycle 2. 28-day Cycles. Nuclear medicine "break-through" scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered.	Device: SIR-Spheres 100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin. Drug: Cetuximab Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly. Other Names: C225 Erbitux Drug: Erlotinib Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3. Other Names: Erlotinib Hydrochloride OSI-774 Tarceva Procedure: Break-Through Scan Nuclear medicine "break-through" scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered. Other Names: x-ray

Arm

Intervention/Treatment

Experimental: Arm 1 SIR-Spheres + Cetuximab

Arm 1: SIR-Spheres with yttrium-90 attached and cetuximab. SIR-Spheres Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Nuclear medicine "break-through" scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered.

Device: SIR-Spheres

100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.

Drug: Cetuximab

Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.

Other Names:

C225

Erbitux

Procedure: Break-Through Scan

Nuclear medicine "break-through" scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered.

Other Names:

x-ray

Experimental: Arm 2 SIR-Spheres + Cetuximab + Erlotinib.

Arm 2: SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib. Physicians will assign patients to Arm 1 or Arm 2 based on their discretion. SIR-Spheres on Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Erlotinib start 100 mg by mouth daily starting with Cycle 2. 28-day Cycles. Nuclear medicine "break-through" scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered.

Device: SIR-Spheres

100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.

Drug: Cetuximab

Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.

Other Names:

C225

Erbitux

Drug: Erlotinib

Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.

Other Names:

Erlotinib Hydrochloride

OSI-774

Tarceva

Procedure: Break-Through Scan

Other Names:

x-ray

Outcome Measures

Primary Outcome Measures

Maximum Tolerated Dose (MTD) [8 weeks]
Maximum tolerated dose (MTD) is defined as the highest dose studied in which the incidence of dose limiting toxicities (DLT) was less than 33% of treated population.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with advanced or metastatic cancer in the liver, with measureable or evaluable disease, that is refractory to standard therapy, relapsed after standard therapy, or who have no standard therapy available that improves survival by at least three months
Patients must be >/= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment providing radiation is not delivered to the only site of disease being treated under this protocol
ECOG performance status </= 3.
Patients must have organ and marrow function defined as: • Absolute neutrophil count

/= 500/mL; • Platelets >/=50,000/mL; creatinine </= 2 X ULN; • Total bilirubin </= 2.0; ALT(SGPT) </= 5 X ULN

Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence).
Patients must be able to understand and be willing to sign a written informed consent document.

Exclusion Criteria:

Pregnant or lactating women.
Patients who have had hepatic external beam radiotherapy.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to SIR-Spheres, cetuximab, or erlotinib.
Patients with colorectal cancer with known kRAS mutation
Hepatic arterial anatomy that would prevent catheterization and the administration of SIR-Spheres into the liver.
Greater than 20% arterio-venous shunting of SIR-Spheres to the lungs estimated from a Technetium-99m-macro-aggregated albumin (99mTc-MAA) nuclear medicine break-through scan
Contraindication to angiography and selective visceral catheterization: History of severe allergy or intolerance to any contract media, or atropine. Bleeding diathesis, not correctable by usual forms of therapy that would include medical coagulopathy but not limited to the administration of blood products.
Utilization of capecitabine for the 6 weeks preceding SIR-Spheres therapy and indefinitely following SIR-Spheres therapy as per manufacturer's recommendations due to the increased risk of radiation hepatitis.
Evidence of ascites, biopsy proven cirrhosis, or portal hypertension suggested by the presence of characteristic imaging features on cross-sectional imaging or esophageal varicosities, demonstrated on endoscopy or barium swallow. A diagnostic study to rule out the presence of portal hypertension will not be required unless the findings on cross sectional imaging are suggestive, but not confirmatory.